LIB details Ph3 PCSK9 inhibitor data; Eyenovia seeks ‘strategic alternatives’

Plus, news about In­ozyme and Sen­so­ri­on:

LIB Ther­a­peu­tics touts pos­i­tive Phase 3 cho­les­terol re­sults: The com­pa­ny’s third-gen­er­a­tion PC­SK9 in­hibitor, lero­dal­cibep, achieved a 56% LDL-C re­duc­tion at 52 weeks, ac­cord­ing to da­ta pre­sent­ed Sun­day at the Amer­i­can Col­lege of Car­di­ol­o­gy’s an­nu­al meet­ing. The most com­mon side ef­fects were mild to mod­er­ate in­jec­tion site re­ac­tions. LIB is prepar­ing to file a BLA for lero­dal­cibep this year. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.